Los Angeles, California – June 22, 2015. Vault Pharma (VPI) (www.vaulpharma.com), a biotechnology company developing immune therapies for cancer and infectious diseases, announced the addition of two high profile immune oncology experts to its Scientific Advisory Board. James Mulé Ph.D. and Antoni Ribas M.D. Ph.D. will join scientific founder Leonard Rome Ph.D. and Paul Wender Ph.D. in advising the company on research and development efforts. “This is a tremendous step for VPI,” said Michael Laznicka, CEO. “To have two of the world leaders in cancer immune therapy joining our scientific advisory group is going to make a significant impact to our clinical trial programs.”
VPI-101, VPI’s lead therapeutic, is being prepared for clinical studies for latestage lung cancer. The company is exploring multiple metastatic cancer indications both as a mono-therapy and ultimately in combination with other immune agents such as checkpoint inhibitors. “By recruiting and activating dendritic and T cells to the tumor, we are adding an important treatment
mechanism to the immune therapy milieu,” said Oliver Foellmer, COO. “There are indications from our work in vault vaccines that vault particles have the ability to present targets to and activate the immune system without the typically negative inflammatory response. Pairing this with the chemokine active ingredient in VPI-101 gives us a completely novel approach at stimulating the immune system.”
Read More About Dr. James Mulé >>
Read More About Dr. Antoni Ribas >>
